Hypermutated Gliomas Respond Poorly to Immunotherapy

Area of Science:

• Neuro-oncology
• Cancer genomics
• Immunotherapy

Background:

• High tumor mutation burden (TMB) in cancers like melanoma and colorectal cancer often predicts response to immune checkpoint blockade (ICB).
• Gliomas, particularly glioblastomas, are typically considered to have low TMB.
• The response of hypermutated gliomas to ICB is not well understood.

Purpose of the Study:

• To investigate the response of hypermutated gliomas to checkpoint blockade therapy.
• To explore the potential causes and consequences of hypermutation in gliomas.

Main Methods:

• Comparative analysis of glioma mutation burden against other cancer types.
• Assessment of glioma response to checkpoint blockade in preclinical or clinical settings (details not provided in abstract).
• Investigation into the association between temozolomide treatment and glioma mutation status.

Main Results:

• Hypermutated gliomas demonstrate limited response to checkpoint blockade, contrasting with other hypermutated malignancies.
• Increased tumor mutation burden in gliomas is associated with shorter patient survival.
• Evidence suggests that temozolomide chemotherapy may induce hypermutation in gliomas through selective pressure.

Conclusions:

• Hypermutation in gliomas confers resistance to checkpoint blockade therapy.
• Temozolomide-induced selective pressure is a likely driver of glioma hypermutation.
• Hypermutation negatively impacts glioma patient survival outcomes.